Bausch Health is down -6.4%, or -67c to $9.74.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health Defends XIFAXAN® Patent
- Bausch Health files patent lawsuit against Amneal Pharmaceuticals
- Bausch Health call volume above normal and directionally bullish
- Bausch Health price target raised to $12 from $9 at RBC Capital
- Bausch Health Canada announces public drug plan listings for UCERIS